Cargando…

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

BACKGROUND: Fluoropyrimidine drugs are extensively used for the treatment of solid cancers. However, adverse drug reactions are a major clinical problem, often necessitating treatment discontinuation. The aim of this study was to identify pharmacogenetic markers predicting fluoropyrimidine toxicity....

Descripción completa

Detalles Bibliográficos
Autores principales:	Loganayagam, A, Arenas Hernandez, M, Corrigan, A, Fairbanks, L, Lewis, C M, Harper, P, Maisey, N, Ross, P, Sanderson, J D, Marinaki, A M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694243/ https://www.ncbi.nlm.nih.gov/pubmed/23736036 http://dx.doi.org/10.1038/bjc.2013.262

Ejemplares similares

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients
por: Amirfallah, Arsalan, et al.
Publicado: (2018)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy
por: Huang, Ming-Yii, et al.
Publicado: (2013)

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
por: García-Alfonso, P., et al.
Publicado: (2021)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
por: Maslarinou, Anthi, et al.
Publicado: (2023)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
por: da Rocha, Jorge E. B., et al.
Publicado: (2021)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
por: Iachetta, Francesco, et al.
Publicado: (2019)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
por: Villalvazo, Priscila, et al.
Publicado: (2021)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
por: Lau, David K., et al.
Publicado: (2023)

The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens
por: Khushman, Moh’d, et al.
Publicado: (2021)

Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer
por: Traylor, Matthew, et al.
Publicado: (2018)

The Diadenylate Cyclase CdaA Is Critical for Borrelia turicatae Virulence and Physiology
por: Jackson-Litteken, Clay D., et al.
Publicado: (2021)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma
por: Rogers, H A, et al.
Publicado: (2012)

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
por: Lin, Shaoyan, et al.
Publicado: (2019)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
por: Saif, Muhammad W, et al.
Publicado: (2016)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
por: Bukhari, Nedal, et al.
Publicado: (2021)

Episodic Src activation in uveal melanoma revealed by kinase activity profiling
por: Maat, W, et al.
Publicado: (2009)

Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients
por: Candy, P A, et al.
Publicado: (2013)

Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas
por: Griffiths, E A, et al.
Publicado: (2007)

A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells
por: Barr, M P, et al.
Publicado: (2005)

Diagnostic precision of image-guided multisampling core needle biopsy of suspected lymphomas in a primary care hospital
por: Loubeyre, P, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_30934ppkgv3rnj9d2dvep9o3uu